The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Telomere-Targeting Agent Demonstrates Tolerability in Advanced NSCLC
As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
FDA Clears New Drug Application for ZW191 in FR⍺+ Ovarian Cancer, NSCLC
Preclinical data support the potential anti-tumor activity and tolerability of a novel FR⍺ topoisomerase I inhibitor in ovarian cancer and NSCLC.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Adaptive De-escalation TKI Therapy in Advanced NSCLC Shows Feasibility
The results of the trial showed that at least 75% of patients with NSCLC harboring driver gene alterations may benefit from this treatment.
Osimertinib Plus Chemotherapy Gains European Approval for EGFR+ NSCLC
Findings from the phase 3 FLAURA2 trial support the European approval of osimertinib/chemotherapy in EGFR-mutated non–small cell lung cancer.